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John M. Hettema1*
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Abstract
Anxiety disorders (ADs) are common mental disorders caused by a combination of genetic and environmental factors. Since
ADs are highly comorbid with each other, partially due to shared genetic basis, studying AD phenotypes in a coordinated
manner may be a powerful strategy for identifying potential genetic loci for ADs. To detect these loci, we performed
genome-wide association studies (GWAS) of ADs. In addition, as a complementary approach to single-locus analysis, we also
conducted gene- and pathway-based analyses. GWAS data were derived from the control sample of the Molecular Genetics
of Schizophrenia (MGS) project (2,540 European American and 849 African American subjects) genotyped on the Affymetrix
GeneChip 6.0 array. We applied two phenotypic approaches: (1) categorical case-control comparisons (CC) based upon
psychiatric diagnoses, and (2) quantitative phenotypic factor scores (FS) derived from a multivariate analysis combining
information across the clinical phenotypes. Linear and logistic models were used to analyse the association with ADs using
FS and CC traits, respectively. At the single locus level, no genome-wide significant association was found. A transpopulation gene-based meta-analysis across both ethnic subsamples using FS identified three genes (MFAP3L on 4q32.3,
NDUFAB1 and PALB2 on 16p12) with genome-wide significance (false discovery rate (FDR] ,5%). At the pathway level,
several terms such as transcription regulation, cytokine binding, and developmental process were significantly enriched in
ADs (FDR ,5%). Our approaches studying ADs as quantitative traits and utilizing the full GWAS data may be useful in
identifying susceptibility genes and pathways for ADs.
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Numerous genetic studies of ADs have been conducted
targeting candidate genes. The most intensively studied candidate
genes are related to neurotransmitter systems involved in the
regulation of anxiety, neuropeptides, and stress response [3].
However, most of these studies have produced inconsistent or
negative results. One of the reasons for inconsistency between
studies may be due to Type I error from poorly-chosen candidates
or Type II error due to small sample size underpowered to detect
individual susceptibility variants of small effect.
Genome-wide association studies (GWAS) have proven to be a
successful method for the identification of common genetic
variants that increase susceptibility to complex diseases or traits.
Recently, several GWAS of ADs such as PD [4,5], PTSD [6,7,8],

Introduction
Anxiety disorders (ADs) are common mental disorders characterized by excessive, prolonged, and debilitating levels of anxiety,
with substantial lifetime prevalence [1]. They are subdivided into
clinical diagnostic categories such as generalized anxiety disorder
(GAD), panic disorder (PD), posttraumatic stress disorder (PTSD),
obsessive-compulsive disorder (OCD) and phobias, based on their
onset, symptoms, and course. ADs are complex diseases that are
caused by a combination of genetic and environmental factors.
Family and twin studies have demonstrated that ADs have
significant familial aggregation, and their heritability estimates
range from 30 to 50% [2,3].
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OCD [9], and phobias [10] have been published. However, the
top findings in these studies have not overlapped with previous
candidates and explained only small proportions of the total
genetic variance. The failure to replicate the same single
nucleotide polymorphisms (SNP) between studies may be attributable to poor power with small sample sizes and allelic and/or
phenotypic heterogeneity across populations.
GWAS usually focus on the most significant individual variants
without considering the global evidence of the gene tested. Unlike
genetic variants that have different allele frequencies, linkage
disequilibrium (LD) structure, and heterogeneity across diverse
human populations, the gene itself is highly consistent across
populations [11]. Gene-based analysis might produce more
consistent results and improve power with a smaller number of
statistical tests. Furthermore, with the gene as the unit of analysis,
biological pathway analysis using available functional information
might facilitate the identification of the pathogenic mechanisms of
complex diseases such as ADs. Therefore, both gene- and
pathway-based analyses could have better statistical power for
detecting susceptibility loci and provide a complementary
approach to single-locus analysis.
Most genetic association studies focus on categorical traits
comparing allele frequencies for diagnosed cases versus controls.
However, if GWAS indicate that multiple genes affect these
disorders, this implies that their genetic liability is distributed
quantitatively rather than qualitatively [12]. For common
disorders like ADs, disease states can be interpreted as being the
extremes of continuous liability dimensions. Therefore, statistical
power can be enhanced by studying the broader distribution than
by dichotomizing the same distribution into cases and controls
[12,13]. Furthermore, previous studies suggest that ADs exhibit
strong lifetime comorbidity, partially due to shared genetic risk
factors between them and with anxious personality traits like
neuroticism [14,15,16]. Therefore, studying AD phenotypes in a
coordinated manner is an alternative approach to increase the
statistical power for identifying susceptibility genes for ADs, as
demonstrated by prior reports from our group [17].
The aim of this study is to conduct GWAS of ADs as
quantitative traits as well as categorical traits in unselected
population samples from the United States consisting of 2540
European American (EA) and 849 African American (AA)
subjects. To optimally utilize the GWAS data sets, we examined
our results at 3 levels: (i) SNP-based analyses (ii) gene-based
analyses and meta-analyses combining these results, and (iii) geneset based analyses.

by genotypic data with ancestry-informative markers [18]. The
data were obtained with permission from dbGaP (Database of
Genotypes and Phenotypes, http://www.ncbi.nlm.nih.gov/gap,
Study Accessions: phs000021.v3.p2 (‘‘Genetic Association Information Network (GAIN)’’) and phs000167.v1.p1 ‘‘nonGAIN’’).
Data for the EA subjects were combined from both the GAIN
(n = 1442) and nonGAIN (n = 1367) datasets. These derived from
the same original sample but had been separately deposited into
dbGaP. Data for the AA subjects were obtained from the GAIN
subsample (n = 979).

Diagnostic measures
All MGS control subjects completed an online psychiatric
screening interview that included the lifetime version of the
Composite International Diagnostic Interview, Short Form (CIDISF) [20]. The CIDI-SF is accurate compared with the full CIDI
[20] and has been used for self-report. Because of its brevity and
cost effectiveness, the CIDI-SF is suitable for an online interview to
screen common psychiatric disorders in the general population
[18]. For those subjects with requisite response data, we applied
DSM-based algorithms to the CIDI-SF responses to obtain the
following six lifetime clinical phenotypes: major depression
(lifetime prevalence of total sample, 30.0%), GAD (18.4%), panic
attacks (2.1%), agoraphobia (6.5%), social phobia (14.3%), and
specific phobia (11.7%). We note that only panic attacks, and not
panic disorder, could be identified due to limitations in the items
included in that section of the CIDI-SF. In the present study, we
used the latter five AD phenotypes for the analyses. Besides
attempting to identify subjects meeting full symptomatic criteria
(‘‘cases’’, score = 2), we also sought to differentiate subjects who
were highly symptomatic but did not meet full criteria (‘‘subsyndromal’’, score = 1) versus those with few or no reported
symptoms (‘‘unaffecteds’’, score = 0). This was operationalized by
either (i) keeping the full symptomatic criteria and removing the
diagnostic requirements of distress/impairment or (ii) reducing the
symptomatic severity or duration. This strategy produced ordered,
rather than classification variables that served as input indicators
for the factor analyses described below. It also identifies more
extreme comparison groups for use in case-control (CC) analyses,
since diagnostic thresholds are defined for clinical purposes and
may not sufficiently differentiate subjects by the risk alleles they
carry.
Given prior evidence supporting shared genetic liability across
these AD phenotypes [14,15,16], we performed factor analyses to
estimate an overall score (factor score; FS) for each subject. Due to
substantial correlation between phenotypic and genetic factor
structure of ADs, this approach should provide FS that represent
shared genetic risk. We conducted the analyses as reported in our
previous paper [17]. Briefly, we entered scores for the five AD
clinical phenotypes into factor analyses in Mplus (version 4) [21].
Exploratory factor analyses with one versus two latent factors each
produced reasonable solutions that adequately fit the data, so, we
chose to use the former solution representing a single common
factor. The overall factor structure was similar across the AA and
EA subjects although their thresholds somewhat differed, indicating differences in frequency of phenotypic scores (prevalence)
between populations. We constrained factor loadings to be equal
across these two samples in order to score all subjects in a manner
that was consistent across populations. A confirmatory factor
analysis was carried out in Mplus to estimate a single FS for each
subject for use as quantitative phenotype in association analyses.

Materials and Methods
Subjects
Data for the analyses came from the ‘‘control’’ sample originally
part of a large schizophrenia study (Molecular Genetics of
Schizophrenia (MGS)). The full MGS control sample is described
in detail elsewhere [18]. Briefly, the available sample consisted of
unrelated subjects selected during 2004–2007 by random digit
dialing from approximately 60,000 US households. Institutional
review board approval was obtained at NorthShore University
HealthSystem. Participants first consented online to use of their
DNA and phenotypic information for the study of any illness or
trait and then signed an identical hard-copy consent at the time of
venipuncture. They were screened and excluded for psychotic and
bipolar disorders for use as a comparison group for genetic
association studies of these more severe psychiatric phenotypes but
were not excluded for other common psychiatric disorders such as
depression and anxiety. Self-reported ancestry [19] was confirmed
PLOS ONE | www.plosone.org
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method [31] implemented in METAL [32] was used. Z-scores for
each gene were combined across samples in a weighted sum, with
weights proportional to the square-root of the sample size for each
study [31]. Given unequal numbers of cases and controls, the
effective sample sizes were calculated as Neff = 4/(1/Ncases+1/
Ncontrols) for the CC analyses.
Gene-set enrichment analysis. Gene-set enrichment analysis was carried out to complement the results from gene-based
GWA analyses and to determine which potential biological
pathways could play a role in ADs. For the analysis, we included
all genes from the gene-based meta-analysis test with a p-value ,
0.01 using the public domain tool provided by the Database for
Annotation, Visualization and Integrated Discovery (DAVID)
bioinformatics platform [33]. We used gene ontology (GO) to
create gene-sets because it provided the largest amount of
information and is well structured. Considering the redundant
nature of annotations, groups of similar annotations were
combined using ‘Functional Annotation Clustering’ (kappa
value.0.5). We selected the best significantly enriched terms of
individual groups. By performing these enrichment analyses, we
attempted to identify whether the genes most associated with ADs
were more prevalent in any known GO terms than would be
expected by chance.

Statistical analyses
To correct for multiple testing, false discovery rate (FDR, qvalue) was calculated, which is an estimate of the proportion of
false discoveries among all significant markers when the
corresponding p-value is used as the threshold for declaring
significance [22]. This approach provides a good way to find true
effects controlling false discoveries and is much less affected by
number of tests, which is an arbitrary factor [23]. Q-values less
than 5% and 25%, respectively, were taken as significant and
suggestively significant for SNP-, gene-, and pathway-based
analyses.
SNP-based analysis. As previously described in detail [24],
DNA samples were genotyped at the Broad Institute using the
Affymetrix 6.0 array. Quality control procedures excluded about
5% of all subjects due to low genotype call rates (,0.95),
heterozygosity outliers, sample duplicates, sex typing discrepancies, or genetic relatedness. SNPs were excluded if a SNP call rate
,0.95, Hardy-Weinberg equilibrium p-value ,161025, and
minor allele frequency (MAF) ,0.05 for both cases and controls.
A total of 626,833 (EA) and 730,090 (AA) autosomal SNPs were
available for further analyses.
We performed regression analyses assuming additive genetic
effects in PLINK [25] to test the main effects of SNPs on the
outcome phenotypes. These included gender and age as covariates, given their strong association with ADs. To account for the
genetic substructure of human populations, multidimensional
scaling (MDS) was used. MDS produced eight components, none
of which were correlated with FS or CC status. Therefore, no
MDS dimensions were included as covariates in the analyses. In
the present study, two phenotypic strategies were compared. First,
linear regression analyses including all subjects were conducted
using FS as a quantitative outcome variable. These scores
incorporate all of the phenotypic information in a statistically
coordinated fashion from the factor analyses. Second, logistic
regression was applied in a CC approach, designating subjects
scoring a ‘‘2’’ for any of the clinical phenotypes as a ‘‘case’’ versus
those scoring ‘‘0’’ on all as ‘‘hyper-normal’’ controls (no full or
subsyndromal AD or major depression).
Quantile-quantile (QQ) plots were used to evaluate overall
significance of the GWA analyses and the potential impact of
population stratification. The inflation factor l was calculated on
the basis of the median chi-square. Haploview 4.2 [26] was used to
create Manhattan plots of p-values from the GWA analyses and to
examine LD between markers. Power calculations were performed
using the program Quanto v1.2.4 (http://hydra.usc.edu/gxe).
Gene-based analysis. Gene-based association analysis in
each population was performed using the versatile gene-based test
for genome-wide association studies (VEGAS) [27]. In brief,
VEGAS tests for association on a per-gene basis, by considering
the p-value of all SNPs within genes (including +/250 kb from the
59 and 39 UTR), accounting for LD and number of SNPs per
gene. For a given gene with n SNPs, association p-values were first
converted to upper tail chi-squared statistics with 1 degree of
freedom (df). The observed gene-based test statistic was then the
sum of all of the chi-squared 1 df statistics within the gene. Using
the Monte Carlo simulation, the empirical gene-based p-value was
calculated as the proportion of simulated test statistics that
exceeded the observed gene-based test statistic.
Previous studies have found consistent genetic effects on
common diseases across different racial groups even if LD patterns
and allele frequencies differ considerably across populations
[11,28–30]. Therefore, to increase statistical power, trans-population meta-analysis of gene-based GWA analyses using FS or CC
was conducted. To test overall significance, Stouffer’s Z-score
PLOS ONE | www.plosone.org

Results
SNP-based analysis
After application of QC parameters, 2540 EA and 849 AA
subjects had FS values available for analyses. Of these, samples for
case-control analysis consisted of 1697 EA subjects (757 cases and
940 controls) and 597 AA subjects (324 cases and 273 controls),
respectively (Table 1). The genomic inflation factors l for the FS
and CC analyses, respectively, were 1.004 and 1.005 in EA and
1.004 and 1.008 in AA, suggesting no significant inflation (Figure
S1 in File S1). The QQ and Manhattan plots for theses SNP-based
GWA analyses are displayed in Figures S1 and S2 in File S1.
Overall, no SNP reached genome-wide significance or suggestive significance for any GWA analyses in either the EA or AA
samples (Table 2 and Figure S2 in File S1). The most significant
signal was observed at SNP rs4692589 located in MFAP3L on
4q32.3 from the results using the FS traits in the EA sample
(p = 8.6361027, q = 0.37; Table 2). Of note, among top findings in
the same analysis was SNP rs2170820, located in TMEM132D
(12q24.3), a gene which has been reported to be associated with
PD in a European Caucasian sample [4].

Gene-based analysis
Using VEGAS, SNPs in each GWA analysis were mapped to
approximately 17,700 genes (FS-EA: 17,660, FS-AA: 17,678, CCEA: 17,655, CC-AA: 17,669). No deviations from the expected
distribution of p-values were observed in the QQ plots of each
gene-based analysis (Figure S3 in File S1). Using FS, a gene
reached a significant q-value (MFAP3L, q = 0.035; Table 3) and
another 11 genes reached suggestive significance (q,0.25) in the
EA sample, whereas none reached suggestive significance in the
AA sample. Using CC, three genes reached suggestive significance
(PF4V1, CXCL1, and CXCL6) in the EA sample, whereas none
reached suggestive significance in the AA sample.
Although there was no full overlap of top associated genes
between the two populations, several genes showed evidence of
association in both. Therefore, we conducted trans-population
meta-analyses of gene-based studies using FS or CC. Top findings
from the gene-based meta-analysis using FS and CC are shown in
Table 3. Three genes met the criteria for genome-wide signifi3
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Table 1. Demographic characteristics of European and African American samples.

Sample

European American

Factor score

2540

849

Gender ratio (female/male)

1.07

1.60

Age (s.d.)

50.8 (16.4)

Case control

757

940

324

Gender ratio (female/male)

1.72

0.67

2.34

1.05

Age (s.d.)

48.3 (14.6)

52.1 (17.2)

44.4 (12.6)

46.2 (13.3)

case

African American
control

case

control

45.6 (13.3)
273

s.d., standard deviation.
doi:10.1371/journal.pone.0112559.t001

At the SNP level, none of the SNP results reached genome-wide
significance. The most likely reasons for the modest p-values seen
in each GWA analysis may be insufficient power to detect very
small genetic effects. In the FS analyses, the power of our samples
were 35% in EA (n = 2540) and 0.6% in AA (n = 849) with an
additive model, a type I error rate of 561028, and an effect size
explaining of 1% total variance. In the CC analyses, the power of
the samples were 0.09% in EA (757 cases vs. 940 controls) and
0.01% (324 cases vs. 273 controls) with the log-additive model, a
type I error rate of 561028, a frequency of 0.25 and an effect size
of 1.2. Therefore, it was not surprising that we could not detect
any locus of genome-wide significance.
While SNP-based GWA analysis focuses on the most significant
individual variants, the gene-based approach tests the global null
hypothesis about the SNPs located per gene. Gene-based tests
allowed us to explore the impact of multiple variants in a gene
even if the gene did not contain any SNP reaching genome-wide
significance. Therefore, we performed gene-based GWA analyses
in the present study. Only when using FS in the trans-population
gene-based meta-analysis did we detect significant association
signals in three genes (MFAP3L on 4q32.3 and NDUFAB1 and
PALB2 on 16p12). We will review these genes in turn.
NDUFAB1 is a subunit of NADH dehydrogenase, a nuclear
encoded subunit of mitochondrial Complex I, which regulates the
redox status of nicotinamide adenine dinucleotide/nicotinamide
adenine dinucleotide hydride (NAD/NADH), and could be
observed in both the cytoplasm and nucleus. NDUFAB1 may be
involved in the regulation of NAD and NADH which influence
fundamental cellular processes such as cellular metabolism, gene
expression, and ion channel regulation, although the function of
NDUFAB1 in ADs remains to be established [35,36].
PALB2 encodes for the protein PALB2, which co-localizes with
BRCA2 in the cell nucleus and promotes its localization and
stability in cellular structure like chromatin and nuclear matrix
[37]. SNP rs420256 in PALB2 has been reported to be associated
with bipolar disorder in Caucasians in previous studies [38,39]. In
our study, rs420259 did not show any significant association with
ADs in either the EA or AA samples (FS-EA p = 0.11; FS-AA
p = 0.37). Rs8062954 on the same LD block (r2 = 0.12, D’ = 1.00)
with rs420259 was nominally associated with ADs using FS in the
AA sample (FS-AA p = 4.8861025).
MFAP3L encodes a transmembrane protein, microfibrillarassociated protein 3-like. The intracellular region of this protein
reportedly contains a cluster of phosphorylation sites and
phosphatidylinositol-3 kinase (PI3K) regulatory subunit, which
suggests the involvement of MFAP3L in the signal transduction of
PI3K/AKT pathway [40]. The PI3K/AKT pathways are known

cance according to the threshold that allows for 5% false discovery
rate (NDUFAB1, PALB2, and MFAP3L; all q-values = 0.028).
Ten other genes in five loci reached a suggestively significant level
using FS (4q32, 11p15, 16p12, 20p13, and 20q11), while three
genes reached the genome-wide suggestive level using CC
(PF4V1, CXCL1, and CXCL6; Table 3).

Gene-set enrichment analysis
We next examined all genes with p,0.01 in the gene-based
meta-analysis to see whether they were enriched with known GO
terms, using DAVID with the whole genome background as a base
set. The numbers of genes included in the analyses were 296 (FS)
and 322 (CC). GO enrichment analysis showed that two terms
using FS (‘‘pattern specification process’’ and ‘‘cytokine binding’’)
and two terms using CC (‘‘nucleoplasm’’ and ‘‘transcription
regulator activity’’) were significantly enriched in ADs (q,0.05)
(Table 4).

Discussion
We report here the results from the GWAS of ADs in two
populations using quantitative and categorical phenotypes at SNP,
gene, and pathway levels. We included 2540 EA and 849 AA
subjects from the MGS control sample and conducted association
analyses using two phenotypic approaches that sought to combine
information across these disorders based upon prior research that
suggests that they possess shared genetic risk factors. The first
utilized factor analysis to extract a single phenotypic score for each
subject for use as a quantitative trait. The second approach
focused on categorical diagnoses that compared allele frequencies
for clinical cases versus hyper-normal controls.
There were notable differences between results obtained using
the two phenotypic methods. Most of the top SNPs were not the
same, although many that were nominally significant in one were
also in the other. The overall significance of SNPs (p- and q-values)
was greater using FS than CC in the EA sample. This is not
surprising, as the factor analytic phenotypes should provide more
powerful targets for genetic association than the categorical
phenotypes for several reasons: quantitative traits generally have
greater information content, and there were more subjects with
useable quantitative traits than categorical traits [34]. However,
this was not the case with the AA sample where the significance of
top findings was similar between the FS and CC analyses
(Tables 2). In the AA sample, the difference in the sample sizes
between the FS and CC analyses was not as large as for the EA
sample, which may result in the smaller differences in power.
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4
12
7
7
7
8

rs7657455

rs10016872

rs2170820

rs1551277

rs12703441

rs6463447

rs4736192

4

rs3097411

1

rs17548918

rs241257

1
10
11
3
11

rs12120353

rs10762651

rs17105932

rs6799682

rs17105964

CC

14
3

rs7141336

FS

4

rs2115691

106,074,793

178,659,210

106,048,675

76,492,123

4,520,856

4,514,682

21,355,095

90,355,981

74,957,318

74,962,555

140,049,007

47,797,795

141,539,176

47,795,842

128,588,656

171,116,951

171,195,418

100,729,499

123,943,822

171,171,820

Position (bp)

GWAS, genome-wide association study; SNP, single nucleotide polymorphism.
Chr, chromosome; bp, base position; OR, odds ratio; FS, factor score analysis; CC, case-control analysis.
A1, minor allele based on whole sample.
*Beta was calculated with FS and OR was calculated with CC.
Genes with SNPs located up to 20 kb down- or upstream were shown.
SNPs with p-values ,1025 were shown.
doi:10.1371/journal.pone.0112559.t002

AA

5

rs12153327

CC

4
11

rs4692589

FS

EA

Chr

rs10893268

SNP

Sample

G

A

T

T

A

A

C

C

C

G

A

A

C

A

C

C

G

C

T

C

A1

0.46

1.79

0.45

0.54

2.13

0.17

0.26

0.19

0.68

0.67

0.073

0.068

20.062

0.068

20.063

20.061

20.064

20.064

20.069

20.067

Beta (OR)*

Table 2. Top findings of SNP-based GWAS in the European (EA) and African American (AA) samples.

8.74E-06

7.53E-06

6.91E-06

6.06E-06

3.08E-06

9.09E-06

8.75E-06

5.83E-06

6.58E-06

4.45E-06

9.24E-06

7.60E-06

6.97E-06

6.88E-06

4.63E-06

3.97E-06

2.90E-06

2.02E-06

1.18E-06

8.63E-07

p

0.99

0.99

0.99

0.99

0.99

1.00

1.00

1.00

0.90

0.90

0.53

0.53

0.53

0.53

0.48

0.48

0.45

0.42

0.37

0.37

q

GUCY1A2

GUCY1A2

DUPD1

TTC7B

CXCL1

CXCL1

PKD1L1

PKD1L1

TMEM132D

MFAP3L

OR8A1

MFAP3L

Gene
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4
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16
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11

16
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5

11

MFAP3L

AADAT

UBFD1

EARS2

DCTN5

CTNNBL1

VSTM2L

GGA2

C11orf40

COG7

SRXN1

TARS

OR52I2

4

4

CXCL1

CXCL6

74,921,276

74,953,972

74,937,876

4,564,618

33,476,654

575,267

23,307,316

4,549,228

23,383,143

35,964,912

35,755,847

23,560,307

23,440,834

23,476,362

171,217,947

171,144,322

23,521,983

23,499,835

Start (bp)

74,923,341

74,955,817

74,939,062

4,565,671

33,503,953

581,890

23,372,004

4,555,626

23,429,309

36,007,161

35,933,934

23,588,683

23,476,197

23,493,211

171,247,947

171,184,004

23,560,179

23,515,140

Stop (bp)

1.27E-04

8.51E-05

6.64E-05

2.49E-04

2.27E-04

1.60E-04

1.32E-04

1.03E-04

9.89E-05

9.20E-05

6.80E-05

5.71E-05

4.41E-05

3.66E-05

1.64E-05

4.78E-06

4.37E-06

4.04E-06

0.37

0.37

0.37

0.29

0.29

0.22

0.19

0.16

0.16

0.16

0.15

0.14

0.13

0.13

0.072

0.028

0.028

0.028

19

32

29

51

17

42

29

54

19

39

76

17

22

17

27

40

17

14

nSNPs

q

p

Genes with q-values ,5% or ,25% in either EA, AA, or meta-analysis of the two populations were shown.
GWA, genome-wide association; Chr, chromosome; bp, base position; nSNPs, number of SNPs located within the gene.
FS, factor score analysis; CC, case-control analysis.
doi:10.1371/journal.pone.0112559.t003

4

PF4V1

CC

16

PALB2

Chr

NDUFAB1

FS

Gene

EA

Meta-analysis

1.00E-05

7.00E-06

4.00E-06

1.68E-04

1.63E-04

4.79E-03

7.10E-05

8.30E-05

9.60E-05

6.07E-04

1.05E-03

1.13E-04

4.10E-05

2.00E-05

3.40E-05

2.00E-06

6.00E-06

9.00E-06

p

Table 3. Meta-analysis of gene-based GWA analyses in European-American (EA) and African-American (AA) samples.

0.059

0.059

0.059

0.25

0.25

0.83

0.18

0.18

0.19

0.54

0.68

0.20

0.12

0.09

0.12

0.035

0.053

0.053

q

30

48

44

56

25

47

32

59

22

40

83

22

25

18

27

43

23

16

nSNPs

AA

9.45E-01

8.96E-01

9.61E-01

4.17E-01

3.98E-01

7.76E-03

4.44E-01

3.41E-01

3.02E-01

5.97E-02

2.21E-02

1.73E-01

2.86E-01

3.84E-01

1.50E-01

3.59E-01

1.78E-01

1.26E-01

p

0.99

0.98

0.99

0.98

0.98

0.98

0.98

0.98

0.98

0.98

0.98

0.98

0.98

0.98

0.98

0.98

0.98

0.98

q
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Table 4. GO term enrichment analysis based on the results from the meta-analysis of gene-based GWAS in European and African
American samples.

GO term

Count

%

Fold Enrichment

p

q

FS
GO: 0007389

B: pattern specification process

14

5.0

3.6

0.0002

0.0025

GO: 0019955

M: cytokine binding

9

3.2

5.5

0.0002

0.0030

GO: 0000793

C: condensed chromosome

7

2.5

3.6

0.0132

0.16

GO: 0030155

B: regulation of cell adhesion

7

2.5

3.5

0.0154

0.23

GO: 0016563

M: transcription activator activity

13

4.6

2.1

0.0196

0.24

CC
GO: 0005654

C: nucleoplasm

26

9.2

2.0

0.0015

0.019

GO: 0030528

M: transcription regulator activity

40

14.1

1.6

0.0017

0.024

GO: 0009952

B: anterior/posterior pattern formation

8

2.8

3.8

0.0049

0.078

GWAS, genome-wide association study; FS, factor score analysis; CC, case-control analysis.
B, biological process; M, molecular function; C, cellular component.
doi:10.1371/journal.pone.0112559.t004

for regulating metabolism, cell growth, and cell survival [41].
Recent studies have indicated that both dopamine and serotonin
partially exert their actions by modulating the activity of AKT
[42,43]. Furthermore, chromosome 4q32 region was suggested to
be associated with ADs (PD, SAD, and phobia) in a previous
linkage study [44], although this region was not confirmed in a
recent meta-analysis of linkage data for ADs [45].
To further explore the GWAS data, we took a pathway-based
approach, providing complementary information to single-marker
and gene-based methods. In the GO term enrichment analyses, we
found two terms (‘‘pattern specification process’’ and ‘‘cytokine
binding’’) using FS and two terms (‘‘nucleoplasm’’ and ‘‘transcription regulator activity’’) using CC to be significantly enriched in
ADs, based on the results from the trans-population gene-based
meta-analysis. As observed in the SNP- and gene-based analyses,
the significance of the top pathways was greater using FS than CC
(Table 4). Among these significant pathways, one intriguing
pathway is ‘‘cytokine binding’’, proteins of which function to
control the survival, growth and differentiation of tissues and cells
via interaction with cytokines. Recent studies have suggested that
inflammation of neurons and inflammatory cytokine production
contribute to the pathophysiology of depression and anxiety [46].
Actually, cytokines and their signaling pathways have significant
effects on the metabolism of multiple neurotransmitters such as
serotonin, dopamine, and glutamate and on synaptic plasticity
[47]. An increase in inflammatory markers such as IL-1, IL-6,
TNF-alpha, and IFN-gamma have been documented in ADs
including PTSD, PD, and OCD as well as anxiety-related
personality traits such as neuroticism [46]. The genes in the
significant pathways are worthy of follow-up in the future research.
Several limitations in this study should be addressed. First, in
the present study, we did not perform replication analyses of the
top findings identified in the SNP-, gene-, pathway-based analyses.
However, to increase the statistical power, we conducted the metaanalyses of the gene-based analyses by combining the two
populations. In future research, further replication studies are
needed to confirm our findings. Second, the distribution of FS
used for the GWA analyses was not normally distributed. Like
most psychiatric phenotypes, the distribution was quite skewed,
with many of the unaffected subjects falling under a peak at the
lower end of the score. Therefore, p-values for some markers in the
PLOS ONE | www.plosone.org

GWAS might have been biased by this feature of the FS
distribution. We tested this for SNPs on different chromosomes
by comparing normal-theory regression with permutation testing
and did not detect major differences. Third, the gender ratio
differs significantly between cases and controls in both EA and AA
samples, which may affect results. Therefore, we conducted the
analyses controlling for gender and age instead of conducting
gender-specific analyses because it reduce the statistical power.
Fourth, the gene- and pathway-based analyses assumed that the
local SNPs only modify the function of the local gene. Thus, both
cis and trans regulation of the genes should be considered in the
future analyses [48]. Fifth, since the sample size of the EA sample
was much larger than the AA sample, most of the top findings in
the gene-based meta-analysis were found in the EA sample.
Therefore, caution is needed to interpret the results given genetic
heterogeneity between the two populations.
In conclusion, our results demonstrate the potential advantage
of studying AD phenotypes as quantitative traits for identifying
shared susceptibility genes. In addition, our study provides a
strategy to utilize the full information of GWAS to find new genes
and pathways that would be missed in a single SNP analysis.
Further studies are necessary to confirm our findings and clarify
the underlying mechanisms of ADs.

Supporting Information
Figure S1 in File S1 Quantile-quantile (QQ) plots
of each SNP-based genome-wide association analysis. (a)
FS-EA, (b) FS-AA, (c) CC-EA, (d) CC-AA. FS, factor score
analysis; CC, case-control analysis; EA, European Americans; AA,
African Americans. Figure S2 in File S1 Manhattan plots of
each genome-wide association analysis. (a) FS-EA, (b) FSAA, (c) CC-EA, (d) CC-AA. FS, factor score analysis; CC, casecontrol analysis; EA, European Americans; AA, African Americans. Figure S3 in File S1 Quantile-quantile (QQ) plots of
gene-based genome-wide association analysis. (a) FS-EA,
(b) FS-AA, (c) CC-EA, (d) CC-AA. FS, factor score analysis; CC,
case-control analysis; EA, European Americans; AA, African
Americans.
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Genomewide association analysis followed by a replication study implicates a
novel candidate gene for neuroticism. Arch Gen Psychiatry 65: 1062–1071.
24. Shi J et al. (2011) Genome-wide association study of recurrent early-onset major
depressive disorder. Mol Psychiatry 16: 193–201.

PLOS ONE | www.plosone.org

8

November 2014 | Volume 9 | Issue 11 | e112559

